Questions? Call 800-624-6242 About | Ordering | New Menu | Items in cart [0] SEARCH

HARDBACK price:$39.00 add to cart Rights & Permissions Free PDF Access Sign in to download PDF book and chapters Free Resources PDF SUMMARY PDF Report Brief Display this book on your site! Related Titles Adverse Effects of Vaccines: Evidence and Causality Preventing HIV Infection among Injecting Drug Users in High Risk Countries: An Assessment of the Evidence Other Related Titles Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C (2010) Board on Population Health and Public Health Practice (BPH) Citation Manager Export the bibliographic data for this book in your chosen format Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Citation Manager . "Appendix B: Public Meeting Agendas." Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press, 2010. Please select a format: Page 215   E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. B Public Meeting Agendas FIRST MEETING-DECEMBER 4, 2008 National Academy of Sciences Building, Washington, DC Welcome and opening statement Palmer Beasley, Committee Chair Charge to the committee John Ward, Centers for Disease Control and Prevention (CDC) Chris Taylor and Martha Saly, National Viral Hepatitis Roundtable Presentations to the committee Dale Hu, CDC Broad Overview of Hepatitis B Cindy Weinbaum, CDC Broad Overview of Hepatitis C Lorren Sandt, Caring Ambassadors Program Hepatitis C: Moving Beyond the Silence Page 215 Front Matter (R1-R20) Summary (1-18) 1 Introduction (19-40) 2 Surveillance (41-78) 3 Knowledge and Awareness About Chronic Hepatitis B and Hepatitis C (79-108) 4 Immunization (109-146) 5 Viral Hepatitis Services (147-208) Appendix A: Committee Biographies (209-214) Appendix B: Public Meeting Agendas (215-218) Index (219-232)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 215
Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C B Public Meeting Agendas FIRST MEETING-DECEMBER 4, 2008 National Academy of Sciences Building, Washington, DC Welcome and opening statement Palmer Beasley, Committee Chair Charge to the committee John Ward, Centers for Disease Control and Prevention (CDC) Chris Taylor and Martha Saly, National Viral Hepatitis Roundtable Presentations to the committee Dale Hu, CDC Broad Overview of Hepatitis B Cindy Weinbaum, CDC Broad Overview of Hepatitis C Lorren Sandt, Caring Ambassadors Program Hepatitis C: Moving Beyond the Silence

OCR for page 216
Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C Joan Block, Hepatitis B Foundation Hepatitis B: Time for Zero Tolerance Public comment period SECOND MEETING-MARCH 3, 2009 The National Academies Beckman Center, Irvine, California Welcome and opening statement Palmer Beasley, Committee Chair Presentations to the committee Gary Heseltine Lead Consultant, Viral Hepatitis Team, Council of State and Territorial Epidemiologists Surveillance Strengths and Weaknesses William Rogers Director of CMS, Physician’s Regulatory Issues Team Viral Hepatitis Prevention Policies and Programs, Centers for Medicare and Medicaid (CMS) Tanya Pagán Raggio Ashley Director, Office of Minority Health and Health Disparities, and Chief Medical Officer, HRSA Community Health Centers: Health Resources and Services Administration (HRSA) Policies and Programs Daniel Raymond Policy Director, Harm Reduction Coalition Hepatitis C Prevention: Harm Reduction David Bell Associate Director for Science and Global Activities, Division of Viral Hepatitis, Centers for Disease Control and Prevention Global Viral Hepatitis Burden: Implications for the US and CDC Response

OCR for page 217
Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C Mark Kane Former Director of the Children’s Vaccine Program, PATH Global Control Programs and HBV Immunization Question and answer period

OCR for page 218
Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C This page intentionally left blank.